Search details
1.
RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes.
N Engl J Med
; 390(11): 1009-1021, 2024 Mar 14.
Article
in English
| MEDLINE | ID: mdl-38477988
2.
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus Vaccine in Infants 6-7 Months of age: A Phase 1/2 Randomized Trial.
J Infect Dis
; 229(1): 95-107, 2024 Jan 12.
Article
in English
| MEDLINE | ID: mdl-37477875
3.
Safety and Immunogenicity of Respiratory Syncytial Virus Pre-fusion Maternal Vaccine Co-administered with Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
J Infect Dis
; 2023 Dec 22.
Article
in English
| MEDLINE | ID: mdl-38133639
4.
Incidence of Cytomegalovirus Primary and Secondary Infection in Adolescent Girls: Results From a Prospective Study.
J Infect Dis
; 228(11): 1491-1495, 2023 11 28.
Article
in English
| MEDLINE | ID: mdl-37340664
5.
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age.
J Infect Dis
; 227(11): 1293-1302, 2023 05 29.
Article
in English
| MEDLINE | ID: mdl-36484484
6.
Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus Vaccine (RSVPreF3) in Mothers and Their Infants: A Phase 2 Randomized Trial.
J Infect Dis
; 228(3): 299-310, 2023 08 11.
Article
in English
| MEDLINE | ID: mdl-36722147
7.
Three Dose Levels of a Maternal Respiratory Syncytial Virus Vaccine Candidate Are Well Tolerated and Immunogenic in a Randomized Trial in Nonpregnant Women.
J Infect Dis
; 225(12): 2067-2076, 2022 06 15.
Article
in English
| MEDLINE | ID: mdl-34146100
8.
Incidence of Respiratory Syncytial Virus Lower Respiratory Tract Infections During the First 2 Years of Life: A Prospective Study Across Diverse Global Settings.
J Infect Dis
; 226(3): 374-385, 2022 08 26.
Article
in English
| MEDLINE | ID: mdl-35668702
9.
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Clin Infect Dis
; 70(10): 2073-2081, 2020 05 06.
Article
in English
| MEDLINE | ID: mdl-31340042
10.
Immunogenicity and Safety of 3 Formulations of a Respiratory Syncytial Virus Candidate Vaccine in Nonpregnant Women: A Phase 2, Randomized Trial.
J Infect Dis
; 220(11): 1816-1825, 2019 10 22.
Article
in English
| MEDLINE | ID: mdl-31418022
11.
Safety and Immunogenicity of 3 Formulations of an Investigational Respiratory Syncytial Virus Vaccine in Nonpregnant Women: Results From 2 Phase 2 Trials.
J Infect Dis
; 217(10): 1616-1625, 2018 04 23.
Article
in English
| MEDLINE | ID: mdl-29401325
12.
A Randomized, Controlled, Observer-Blinded Phase 1 Study of the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine With or Without Alum Adjuvant.
J Infect Dis
; 215(1): 24-33, 2017 Jan 01.
Article
in English
| MEDLINE | ID: mdl-27694633
13.
Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children.
J Pediatric Infect Dis Soc
; 12(5): 273-281, 2023 May 31.
Article
in English
| MEDLINE | ID: mdl-37142551
14.
ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves.
Nat Commun
; 13(1): 6142, 2022 10 17.
Article
in English
| MEDLINE | ID: mdl-36253363
15.
Hamster neogenin, a host-cell protein contained in a respiratory syncytial virus candidate vaccine, induces antibody responses in rabbits but not in clinical trial participants.
Hum Vaccin Immunother
; 16(6): 1327-1337, 2020 06 02.
Article
in English
| MEDLINE | ID: mdl-31951765
16.
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
Pediatr Infect Dis J
; 28(4 Suppl): S66-76, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19325449
17.
Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Pediatr Infect Dis J
; 28(4 Suppl): S77-88, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19325450
18.
Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Pediatr Infect Dis J
; 28(4 Suppl): S97-S108, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19325452
19.
The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Pediatr Infect Dis J
; 28(4 Suppl): S89-96, 2009 Apr.
Article
in English
| MEDLINE | ID: mdl-19325451
20.
Maternal immunization: where are we now and how to move forward?
Ann Med
; 50(3): 193-208, 2018 05.
Article
in English
| MEDLINE | ID: mdl-29308916